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Mucolipin-1 positively regulates TLR7 responses in dendritic 
cells by facilitating single stranded RNA transportation to 
lysosomes 
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Abbreviation 
Ab: antibody 
AP2: adapter-related protein complex-2 
ARF6: ADP-ribosylation factor 6 
BM-cDCs: bone marrow derived conventional dendritic cells 
BM-pDCs: bone marrow derived plasmacytoid dendritic cells 
C/EBP!: CCAAT/enhancer binding protein beta 
CD: cluster of differentiation 
DAMPs: Damage Associated Molecular Patterns 
DMSO: dimethyl sulfoxide 
EDTA: etylenediaminetetraacetic acid 
ELISA: enzyme linked immunosorbent assay 
ER: endoplasmic reticulum 
FACS: fluorescence activated cell sorter 
FBS: fetal bovine serum 
FLT3: fms-related tyrosin kinase 3 
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GM-CSF: granulocyte-macrophage colony-stimulating factor 
HIV-1: human immunodeficiency virus-1 
IFN-": interferon alpha 
IgG: immunoglobulin G 
IL-6: interleukin-6 
IL-12p40: interleukin-12p40 
IRFs: interferon regulatory factors 
LPS: lipopolysaccharide 
LROs: lysosome related organelles 
M-CSF: macrophage colony-stimulating factor 
mAb: monoclonal antibody 
mRNA: messenger RNA 
NAs: nucleic acids 
NF-#B: nuclear factor kappa B 
PAMPs: Pathogen Associated Molecular Patterns 
PCR: polymerase chain reaction 
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PI3K: phosphatidylinositol 3-kinases 
PRAT4A: A protein associated with TLR4 
PRRs: Pattern Recognition Receptors 
PtdIns: phosphatidylinositol 
PtdIns(3,5)P2: Phosphatidylinositol (3,5) bisphosphate 
PtdIns(3)P: Phosphatidylinositol (3) bisphosphate 
PVDF: polyvinylidene difluoride 
RA: rheumatoid arthritis 
RASFs: rheumatoid arthritis synovial fibroblasts 
SDS-PAGE: sodium dodecyl sulfate polyaclylamidegel electrophoresis 
SLE: systemic lupus erythematosus 
ssRNA: single stranded RNA 
TBST: tris buffered saline tween  
TLRs: Toll like receptors 
TNF-": tumor necrosis factor alpha 
Unc93b1: Unc-93 homolog B1 
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1. Introduction 
1.1 Innate immunity. 
  Innate immunity is the first line of defense against infections [1]. The cells belonging 
to innate immunity are rapidly activated by microbes before the development of 
adaptive immune responses. In response to microbes, innate immunity stimulates 
adaptive immune responses and is able to influence the nature of the adaptive responses 
to make them optimally effective against different types of pathogens. Many cells and 
tissues are endowed with the ability to contribute to innate immune activity. The 
specificities of innate immune system have evolved to offense the invaded microbes and 
are different from those of the adaptive immune system. 
  The innate immunes system recognizes molecular structures that are conserved 
within a class of microbes. The small molecular motifs that can stimulate innate 
immunity are called Pathogen Associated Molecular Patterns (PAMPs). Pathogens 
including viruses, gram-negative bacteria, gram-positive bacteria and fungi express 
varied PAMPs such as nucleic acids and proteins that are unique to microbes. The 
innate immune system also recognizes the endogenous molecules that are released from 
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damaged tissues or dying cells. These substances are called Damage Associated 
Molecular Patterns (DAMPs) [2, 3]. 
1.2 Toll like receptors (TLRs) family. 
  Several families of cellular receptors distributed in different locations in cells are 
found to recognize PAMPs and DAMPs. These innate immune receptors are called 
Pattern Recognition Receptors (PRRs). Among PRR families, Toll like receptors 
(TLRs) family is one of the best described. TLRs are type I transmembrane proteins 
with ectodomains containing leucine rich repeats, transmembrane domain and 
intracellular Toll interleukin 1 (IL-1) receptor (TIR) domain that is involved in the 
recruitment of signaling adaptor molecules [4]. 
  To date, 10 functional TLRs are found in humans and 13 TLRs are found in mice.  
TLR1-9 are highly conserved among both species. TLR11, TLR12 and TLR13 have not 
been functioning in the human genome. The distribution of TLRs has been considered 
to divide into two groups. TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11 are expressed 
on the cell surface, whereas TLR3, TLR7, TLR8 and TLR9 are expressed in 
intracellular compartments like endoplasmic reticulum (ER), endosome, lysosome and 
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lysosome related organelles (LROs) [2, 3, 5]. Recently, TLR9 is shown to expressed on 
the cell surface in many types of cells. The functions of cell surface TLR9 have not 
been clarified [6].  
1.3 Toll like receptors and their ligands. 
  A variety of molecular patterns of microorganisms and self-components are 
recognized by different TLRs (Table 1). TLR2/TLR1 and TLR2/TLR6 heterodimers 
sense various components from bacteria, mycoplasma, fungi and viruses. These 
components include the lipoproteins of bacteria and mycoplasma. TLR4-MD2 
recognizes lipopolysaccharide (LPS) derived from the outer membrane of 
Gram-negative bacteria. TLR5 recognizes flagellin from flagellated bacteria. TLR11, 
which has close homology to TLR5, recognizes uropathogenic bacteria and a 
profilin-like molecule derived from protozoan Toxoplasma gondii. TLR3, TLR7, TLR8, 
and TLR9 recognize nucleic acids (NAs) derived from viruses, bacteria and dead cells 
[7]. 
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Table 1. Toll like receptors and their ligands. 
TLR Localization Species Natural ligands Synthetic ligands Recognized pathogens 
TLR1 Plasma 
membrane 
Humans 
and Mice 
Triacyl lipopeptides Pam3CSK4 Bacteria 
TLR2 Plasma 
membrane 
Humans 
and Mice 
Lipoproteins, 
peptidoglycan, LTA, 
zymosan and mannan 
Pam3CSK4 Bacteria, viruses, parasites, 
self 
TLR3 Endolysosome Humans 
and Mice 
dsRNA Poly I:C and Poly U Virus 
TLR4 Plasma 
membrane 
Humans 
and Mice 
LPS, RSV, MMTV fusion 
protein, mannans, and 
glycoinositolphosphate 
from Trypanosoma spp. 
Lipid A derivatives Gram-negative bacteria, 
virus and self. 
TLR5 Plasma 
membrane 
Humans 
and Mice 
Flagellin Unknow Bacteria 
TLR6 Plasma 
membrane 
Humans 
and Mice 
Diacylipopetides, LTA and 
zymosan. 
MALP2 and FSL-1 Bacteria and Virus 
TLR7 Endolysosome Humans 
and Mice 
GU-rich ssRNA and short 
dsRNA 
Imidazoquinolines 
and guanosine 
analogues 
Virus, Bacteria and self 
TLR8 Endolysosome Humans 
and Mice 
GU-rich ssRNA, short 
dsRNA and bacterial RNA 
(For human TLR8) 
Imidazoquinolines 
and guanosine 
analogues 
Virus, Bacteria and self 
TLR9 Endolysosome Humans 
and Mice 
CpG DNA and hemozoin 
from Plasmodium spp. 
CpG ODNs Bacteria, Virus, Protozoa 
and self 
TLR10 Endolysosome Humans Unknown Unknow Unknow 
TLR11 Plasma 
membrane 
Mice Profilin and flagellin Unknow Apicomplexan parasites and 
bacteria (including 
Salmonella spp. and UPEC) 
TLR12 Endolysosome Mice Profilin Unknow Apicomplexan parasites 
TLR13 Endolysosome Mice Bacterial 23S rRNA with 
CGGAAAGACC motif 
Unknow Gram-negative and 
Gram-positive bacteria 
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1.4 Localization, trafficking and processing of Toll like receptors. 
  In resting cells, accessary proteins are required for the trafficking of TLRs. MD2 is 
essential for the translocation of TLR4 from the Golgi to the plasma membrane [8]. 
Unc-93 homolog B1 (Unc93b1) mediates TLR3, TLR7, TLR8 and TLR9 trafficking 
from ER to endosome [9-12]. Recent studies reveal that Unc93b1 regulates cell surface 
expression of TLR5 and TLR9 [6, 13]. Internalization of cell surface TLR9 is mediated 
by cooperation of Unc93b1 and adapter-related protein complex-2 (AP2) [14]. A 
protein associated with TLR4 (PRAT4A) is essential for the proper folding of TLRs 
(except TLR3) [15], and thereby required for TLR egress from the ER (Fig. 1). 
PRAT4A (M145K) mutation prevents stimulation-induced TLR9 relocation and 
weakens the association with TLR4 [16, 17]. Previous reports show that CpG DNA 
induces TLR9 conformation change [18], and this change is due to the cleavage of 
TLR9. Moreover, cleavage of TLR7 and TLR3 is proved to be important in NAs 
sensing [19].  
1.5 Localization and trafficking of Toll like receptor ligands. 
  It has become increasingly evident that the localization and transportation of TLRs is 
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important to sense their ligands. Latz et al. report that CpG DNA moves into early 
endosomes and is subsequently transported to a tubular lysosomal compartment [18]. 
Simultaneously TLR9 redistributes from the ER to CpG DNA-containing compartment 
[18, 20]. It is reported that CD14 contributes to CpG DNA internalization and delivery 
to TLR9 compartments. In addition, CD14 is able to facilitate the uptake of imiquimod, 
the chemical ligand of TLR7 [21].  
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Figure 1. TLRs distribution and accessary proteins for TLRs trafficking. TLRs are 
divided to two groups depending on their distribution. TLR1, TLR2, TLR4, TLR5, and 
TLR6 are localized on the cell surface, whereas intracellular TLRs including TLR3, 
TLR7, TLR8, and TLR9 reside in endolysosomes. TLR9 is also expressed on the cell 
surface and the internalization is mediated by AP2. Both Unc93b1 and PRAT4A are 
required for TLRs exit ER and transportation to cell surface or endosome. 
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1.6 Toll like receptor induced inflammatory mediators. 
  Activation of TLRs signaling pathways leads to the nuclear translocation of a set of 
transcription factors, including nuclear factor kappa B (NF-#B), activator protein 1 
(AP-1), interferon regulatory factors (IRFs) and CCAAT/enhancer binding protein beta 
(C/EBP!). These factors regulate their target genes and remodel chromatin [22]. Thus 
the protein levels of cytokines, chemokines, and IFNs are elevated after TLRs activation. 
IL-6 stimulates the inflammatory processes in many autoimmune diseases such as 
rheumatoid arthritis (RA). Type I IFNs are reported to cause chronic inflammation 
diseases such as systemic lupus erythematosus (SLE). TNF-! is reported to be involved 
in atherosclerosis and RA [23-25]. 
1.7 Aberrant transportation of Nucleic Acids (NAs) predisposes to autoimmune 
diseases. 
  TLR7 and TLR9 erroneously respond to self-derived NAs, inducing anti-nuclear 
autoantibody production in murine models of SLE [26-28]. Self-pathogen 
discrimination by TLR7 or TLR9 is error-prone and needs to be strengthened by 
mechanisms restricting RNA/DNA-sensing in endolysosomes rather than on the cell 
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surface. Self-derived RNA/DNA is rapidly degraded by RNase or DNase, whereas 
microbial RNA/DNA is resistant to degradation because it is encased in bacterial cell 
walls or viral particles. Microbial RNA/DNA is therefore able to reach endolysosomes 
to stimulate TLR7 or TLR9 [29]. In the disease state, however, self-derived NAs are 
shown to become resistant to degradation and reach endolysosomes. Previous reports 
have revealed that in psoriasis, self-derived DNA and self-derived RNA form 
complexes with cationic antimicrobial peptide LL37, and traffic to endosomes, where 
TLR7 and TLR9 are localized [28, 30]. In SLE, self-derived DNA and self-derived 
RNA form complexes with autoantibodies and traffic to endosomes via Fc$ (CD32) 
receptor-mediated endocytosis [31, 32]. Rheumatoid arthritis (RA) is characterized by 
persistent inflammation of the synovial membrane [33]. Emerging evidences reveal that 
expression of TLR7 is significantly elevated in RA synovial fibroblasts (RASFs) [34, 
35]. TLR7 erroneously responds to self-derived ssRNA can exacerbate RA by inducing 
TNF-" production [35]. Repeated low dose administration of synthetic TLR7 ligands, 
which results in hyporesponsiveness or tolerance of TLR7, attenuates the joint 
inflammation in a RA model [36]. A defective TLR9 response, which is caused by the 
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inhibition of cathepsin K, suppresses autoimmune inflammation of the joints in RA [37]. 
These findings highlight the important regulatory functions of TLRs in autoimmune 
disease. 
1.8 Molecular mechanism underlying transportation of Toll like receptor 7 and 9. 
  To limit NA-sensing by TLR7 or TLR9 in endolysosomes, TLR7/9 transportation has 
to be tightly controlled. If TLR9 is forced to be expressed on the cell surface, TLR9 
signals in response to extracellular self-derived DNA, leading to systemic lethal 
inflammation [38]. Trafficking of TLR7 and TLR9 are dependent on Unc93B1, a 
multiple transmembrane protein [9, 39]. Unc93B1 is associated with TLR7 or TLR9 
and is essential for their transportation. In mice harboring 3d mutation replacing 412nd 
histidine with arginine in the Unc93B1 gene, TLR7 and TLR9 fail to traffic out of the 
ER and to respond to NAs in endolysosomes. Furthermore Unc93B1 also has a role in 
balancing TLR7 and TLR9 responses. A point mutation of aspartic acid at position 34 
(D34A) alters the balance of TLR7 and TLR9 toward TLR7 dominant [40, 41], leading 
to TLR7-dependent systemic lethal inflammation in vivo.  
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1.9 Roles of Phosphatidylinositides in transportation of RNA/DNA. 
When compared to sensor transportation, much less is known about molecular 
mechanism underlying NAs transportation. Wu. et al. show that inhibition of 
ADP-ribosylation factor 6 (ARF6) impaired cellular uptake of CpG ODN into 
endosome through the impaired class III phosphatidylinositol 3-kinases (PI3K) activity 
[42]. Class III PI3K (also known as Vps34) is important in converting 
phosphatidylinositol (PtdIns) into Phosphatidylinositol (3) bisphosphate (PtdIns(3)P) 
that is predominant phosphoinositide in early endosomes and autophagosomes [43]. 
PtdIns(3)P is responsible for recruiting a spectrum of cytosol-localized proteins to these 
compartments. PtdIns(3)P can be converted into Phosphatidylinositol (3,5) bisphosphate 
(PtdIns(3,5)P2) by the phosphatidylinositol 5-kinase (PtdIns(5)K) PIKfyve complex (Fig. 
2). Hazeki et al. show that PIKfyve inhibitor YM201636 induces accumulation of 
CpG-B in early endosomes in a macrophage cell line, and thereby impairs TLR9 
responses [44]. 
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1.10 Transient receptor potential mucolipin-1, mucolipin-2 and mucolipin-3 
(TRPML1, 2 and 3) function as downstream effectors of phosphatidylinositides. 
  PtdIns(3,5)P2 is reported to directly bind to amino acid terminus of mucolipin-1 
(TRPML1) and induces Ca2+ release [45] (Fig. 2). Mucolipin superfamily of ion 
channels are localized to the endosomal pathways that mediate numerous cellular 
functions. The mucolipin subfamily consists of three members: mucolipin-1 (TRPML1), 
mucolipin-2 (TRPML2) and mucolipin-3 (TRPML3) [45]. Mucolipin-1 has been 
identified as the protein mutated in the lysosomal storage disease (LSD) Mucolipidosis 
type IV that shows aberrant metabolites transportation and enlarged endolysosome [46, 
47]. Likewise, mucolipin-3 is as the one in mice with the varitint-waddler phenotype 
[48]. Mucolipin-1 localizes in late endosomes and lysosomes [49], mucolipin-2 is found 
mainly in lysosomes, and mucolipin-3 shuttles between multiple intracellular 
compartments and the plasma membrane [50]. 
1.11 The role of mucolipin in the endocytic pathways. 
  Endosomes are formed via cargo endocytosis from cell surface or reception 
biosynthetic cargo from the late Golgi complex. The endosomal pathway plays essential 
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role in endocytic membrane traffic, protein sorting, pathogen uptake, antigen 
presentation and signaling [51]. Luminal Ca2+ is also a key regulator of the endosomal 
pathway. Release of Ca2+ from endosomes and lysosomes is required for several steps of 
intracellular trafficking, including fusion and fission events [52]. Ca2+ is important in 
inflammatory responses [53-56] (Fig. 2). Mucolipin subfamily mediates Ca2+ influx and 
efflux. The gain-of-function mutation A419P of mucolipin-3 alters ionic selectivity and 
Ca2+ permeability [48]. The homologous mutation V432P of mucolipin-1 confers Ca2+ 
channel constitutive permeability, along with altered trafficking [57]. 
1.12 The question addressed in this study. 
  Mucolipin-1 deficient cells are impaired in endosomal trafficking and show enlarged 
endolysosomes, which are also observed in cells lacking of PtdIns(3,5)P2 [45]. Previous 
reports show that PtdIns(3,5)P2 has an important role in NAs trafficking, in addition, 
mucolipin-1 is a target of PtdIns(3,5)P2 [44, 45], PtdIns(3,5)P2 may regulate NAs 
trafficking via mucolipin-1. Mucolipidosis type IV cells show impaired transportation 
of metabolites. NAs belong to metabolites, the transportation of NAs therefore may be 
regulated by mucolipin-1. To date, the immunological analysis of mucolipin-1 null mice 
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has not been reported. The present study focused on role of mucolipin-1 in TLR7 and 
TLR9 responses, particularly in clarifying the mechanisms underlying intracellular NAs 
transportation. To address this issue, TLR7 and TLR9 responses in Mcoln1-/- mice were 
studied. Mcoln1-/- cells showed decreased TLR7 responses to single stranded RNA 
(ssRNA), and impaired ssRNA localization in lysosomes. PIKfyve inhibitor 
significantly impaired ssRNA responses and transportation to lysosomes. These results 
suggest a role of PtdIns(3,5)P2-mucolipin-1 axis in ssRNA transportation to the 
lysosomes. 
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Figure 2. Subcellular distribution of PtdIns and mucolipin-1. A schematic cartoon 
of endosomal network. PtdIns in different compartments is indicated by different 
colours. Class III PI3K synthesizes PtdIns(3)P in early endosome. PIKfyve converts 
PtdIns(3)P to PtdIns(3,5)P2. PtdIns(3,5)P2 regulates luminal Ca2+ via activation of 
mucolipin-1. Mucolipin-1 is a Ca2+ channel mainly localizes in late endosome and 
lysosome, and is predicted to have six transmembrane domains with the amino acid 
terminus binding to PtdIns(3,5)P2. Luminal Ca2+ positively regulates lysosome 
exocytosis. 
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2. Materials and Methods 
2.1 Mice 
  Mcoln1-/- mice used for this research project were B6.129-Mcoln1tm1Asoy/Mmmh, stock 
number 034789-MU. They were obtained from the Mutant Mouse Regional Resource 
Center, a NIH funded strain repository (MU MMRRC; U42OD010918; MMRRC ICSC 
– U42OD010983), and were donated to the MMRRC by Abigail Soyombo-Shoola, PhD, 
University of Texas Southwestern Medical Center [58]. C57BL/6 mice were purchased 
from Japan SLC, Inc. (Shizuoka, Japan). Bone marrow chimeric mice (BM chimeric) 
were generated as following protocol. C57BL/6 mice were irradiated at 950 rad at a 
time. 10 million Bone marrow (from femur and tibia) cells from WT or Mcoln1-/- mice 
were intravenously injected into recipients (C57BL/6 mice, 4 wk of age, female). Water 
for mice living were supplemented with neomycin. 72 hr later, the neomycin contained 
water was changed to antibiotics free. BM chimeric mice were used 6 wk after transfer. 
Chimerisms were confirmed by reverse transcription PCR of mRNA from splenic B 
cells, and by impaired cell surface expression of CD23 on B cells from Mcoln1-/- cells. 
Mice were maintained in the animal facility of the Institute of Medical Science, the 
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University  of Tokyo (IMSUT). All animal experiments were approved by the 
Institutional Animal Care and Use Committee. 
2.2 Cells 
2.2.1 Splenic B cells enrichment. 
  Most leukocytes express CD43, in addition to granulocytes, macrophages, monocytes, 
natural killer cells. But resting mature and immature B cells are exception. The 
purification of splenic B cells is based on this principle. The whole spleen was grinded 
by slide glass. Debris was filtered off leaving only the cells. Cells were treated with 1ml 
of room temperature balanced Red Blood Cell lysis buffer (BD PharmLyse BD Science) 
1 min, then stopped by 4 ml Fetal Bovine Serum (Thermo). After centrifugation, flicked 
the cell clump and suspended by RPMI1640 complete culture medium (RPMI1640 
(Gibco), 10 % FBS (Thermo), 100 units/ml penicillin, 100 µg/ml streptomycin, 292 
µg/ml glutamine (Gibco), 50 µM Beta-2-mercaptoethanol (Nacalai Tesque)). 
Determined the cells number, spun down the cells then resuspended the cell pellet in 90 
µl MACS buffer (2 % FBS, 2 mM EDTA, PBS) per 107 cells together with 10 µl CD43 
(Ly-48) MicroBeads (Miltenyi Biotec) incubated 15 min at 4". Washed cells by 
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MACS buffer, then proceeded to magnetic separation. Purity of B cell was evaluated by 
FACSCalibur (BD Biosciences). 
2.2.2 Bone marrow derived conventional dendritic cells (BM-cDCs) and 
plasmacytoid dendritic cells (BM-pDCs). 
  Mice femur and tibia were cut off in sterile condition. 10 ml syringe and 26 mm 
needle were used to wash out bone marrow. Bone marrow (BM) cells were treated with 
Red Blood Cell lysis buffer (BD PharmLyse BD Science). 10#106 cells were cultured in 
RPMI1640 complete culture medium (RPMI1640 (Gibco), 10 % FBS (Thermo), 100 
units/ml penicillin, 100 µg/ml streptomycin, 292 µg/ml glutamine (Gibco), 50 µM 
Beta-2-mercaptoethanol (Nacalai Tesque)) with 10 ng/ml GM-CSF (Peprotech). On the 
day 7, only floating cells were harvested. 15#106 cells were culture in RPMI1640 
complete culture medium (RPMI1640 (Gibco), 10 % FBS (Thermo), 100 units/ml 
penicillin, 100 µg/ml streptomycin, 292 µg/ml glutamine (Gibco), 50 µM 
Beta-2-mercaptoethanol (Nacalai Tesque)) with 100 ng/ml FLT3 ligand (Peprotech). On 
the day 7, both floating cells and attached cells were harvested, and sorted by 
FACSAria Sorting (BD Bioscience). 
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2.3 ELISA 
  1#105 per well of BM-cDCs or BM-pDCs were seeded in 96 flat bottom wells plate 
(Falcon), 24 hr stimulation with TLRs ligands. For mucolipin agonist treatment, cells 
were pre-incubated in 10 µM ML1-SA1 (Calbiochem) for 30 min, followed by 
stimulating with TLRs ligands. For PIKfyve inhibition assay, cells were pre-incubated 
in PIKfyve inhibitor (YM201636 (Calbiochem)) for 15 min, followed by stimulating 
with TLRs ligands. For transfection reagents complex nucleic acids stimulation, ssRNA, 
CpG-B and CpG-A were packaged with lipofactamine 2000 (Invitrogen). Transfection 
methods were based on the manual of lipofactamine 2000. Supernatants of samples 
were harvested to detect inflammatory cytokines such as IL-6, TNF-" and IFN-". 
  Serum samples from BM chimeric mice were obtained 4 days before R848 injection 
as background control (Pre-serum). 2 µg/ 200 µl per mouse of R848 was intravenously 
injected through vena ophthalmica. After 2 hr, serum samples were collected from 
facial blood. Sera or supernatants were diluted by Reagent Diluent (1 % BSA (Sigma), 
1 % Sucrose (Wako)) relied on cytokine production levels and stimuli. IL-6 and 
IL-12p40 was detected from serum samples. 
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  IL-6 and TNF-! were determined by Ready-SET-Go! ELISA (eBioscience), IFN-" 
was measured by VeriKine™ Mouse Interferon Alpha ELISA Kit (PBL Assay Science), 
IL-12p40 was determined by Duo Set ELISA system (R&D systems). Samples plates 
were analyzed by iMark Microplate Absorbance Reader (BIO-RAD). 
2.4 Immunoprecipitation and immunoblotting 
  Toll like receptors processing were utilized co-immunoprecipitaiton and western 
blotting. 2#107 BM-cDCs were lysed in lysis buffer (1 % Triton X100, 20 mM Tris/HCl 
pH 7.4, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 10 % Glycerol, Complete Inhibitor 
(Roche)) for 30 min on ice. Anti-TLR7- or anti-TLR9-coupled agarose beads were 
supplied to the supernatant and rotated for 2 hr at 4°C. After incubation, the beads were 
washed by washing buffer (0.1 % Triton X100, 20 mM Tris/HCl pH 7.4, 150 mM NaCl, 
1 mM CaCl2, 1 mM MgCl2, 10 % Glycerol) and mixed with 2# sample buffer. The 
samples were boiled for 5 min at 96°C and subjected to SDS-PAGE. After 
electrophoresis, proteins in the gel were transferred on PVDF membrane, and the 
membrane was blocked with 3 % skim milk (Difco) in TBST for 1 hr at room 
temperature. Then samples were immunoprobed with anti-TLR7 (polyclonal, 
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eBioscience) or anti-TLR9 (polyclonal, homemade). The signal was visualized by 
Amersham ECL Western Blotting Detection Reagents (GE Healthcare Life Sciences) 
and LAS500 (GE Healthcare Life Sciences). 
2.6 FACSCalibur and FACSAria Sorting 
  During B cell differentiation, maturation and migration, specific markers expressed 
on cell surface. These processes are measured based on detection of cell surface 
markers. 3#105 whole spleen cells and peripheral blood mononucleated cells were 
separated into 96 wells plate. Washed by pre-cold FACS buffer (2.5 % FBS, 0.1 % 
Sodium Azide, 1#PBS) The isotype of antibodies we use wereeBiosciencemouse 
IgG1-Kappa, thus IgG1 Fc receptor blocking with anti-Fc gamma receptor (CD16/32 
eBioscience) was necessary in ahead. Followed by staining with fluorescent dyes 
labeled antibodies (eBioscience) (Table 2). Samples were evaluated by BD 
FACSCalibur Flowcytometor (BD Biosciences). Biotin conjugated TLRs antibodies 
were generated by the Division of Infectious Genetics, IMSUT. 
  FLT3 ligand induced BM-pDC were sorted by B220 and CD11c double positive 
population. FACSAria sorting was exerted by FACSAria co-laboratory (IMSUT). 
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Table 2. Antibodies for FACS analysis. 
eBioscience B220, CD16/32, CD11b, CD11c, CD21, CD23, CD43  
Division of 
Infectious Genetics, 
IMSUT. 
BioA94 (TLR7), BioJ15A7 (TLR9)  
2.7 Trypan blue quenching 
  In order to measure the internalization of ssRNA, trypan blue quenching assay was 
used. 3#105 BM-cDCs were seeded in round bottom 96 wells plates. FITC-conjugated 
RNA9.2s-DR was incubated with BM-cDCs for 1 hr and 2 hr at 37°C. Cells were 
briefly washed by 1#PBS one time, and resuspend in 1#PBS or in 2 mg/ml Trypan Blue 
Stain 0.4 % (Gibco). Fluorescence was evaluated by FACSCalibur (BD Biosciences). 
2.8 Confocal Microscopy 
  2#105 BM-cDCs were seeded on 4 compartments cell culture dish (CellviewTM cell 
culture dish with glass bottom, greiner bio-one). Overnight culture allows the cells to 
adhere to the bottom. Cells were pre-treated with DMSO or 10 µM ML-SA1, and 
incubated with CpG-A-rhodamine, CpG-B-rhodamine, Poly U-rhodamine or 
RNA9.2s-DR-rhodamine for 90 min at 37°C. Supernatant containing ligands were 
removed and supplemented with LysoTracker® Green DND-26 (Life technologies), 
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incubated for 30 min at 37°C. Imaging is performed by LSM710 confocal microscope 
with a #63 NA1.4 Plan-Apochromat oil immersion lens (Carl Zeiss Microscopy). 
Fluorescent images were analysed by LSM710 ZEN software. 
2.9 Ligands 
  Toll like receptors specific ligands (Table 3) were used for analyzing the essential 
role of mucolipin-1 in TLRs function. 
Table 3. Toll like receptors ligands. 
Sigma-Aldrich Lipid A (S.minnesota <Re-595>)  TLR4 
Invivogen Imiquimod (R837) TLR7 
Loxoribine 
R848 
FASMAC Poly U (uuuuuuuuuuuuuuuuuuu) 
RNA9.2s-DR (uguccuucaauguccuucaa) 
Hokkaido System 
Science 
CpG-B 1668 (tccatgacgttcctgatgct) TLR9 
CpG-A 1585 (ggggtcaacgttgagggggg) 
2.10 Statistical analysis 
  Student’s t-test is used for statistical analysis. P value of <0.05 was considered to be 
statistically significant. 
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3. Results 
3.1 No alteration in maturation of bone marrow derived conventional dendritic 
cells (BM-cDCs) and bone marrow derived plasmacytoid dendritic cells 
(BM-pDCs) from Mcoln1-/- mice. 
  BM cells were allowed to differentiate into BM-cDCs or BM-pDCs and stained with 
the maturation markers. BM-cDCs maturation was not altered by mucolipin-1 in terms 
of similar cell surface expression of CD11c in Mcoln1-/- BM-cDCs (Fig. 3A). Cell 
surface expression of CD11c and B220 was not altered in Mcoln1-/- BM-pDCs 
indicating that BM-pDCs maturation was not effected by mucolipin-1 (Fig. 3B).  
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Figure 3. No alteration in maturation of BM-cDCs and BM-pDCs from Mcoln1-/- 
mice. (A) Open histograms showed CD11c expression on WT or Mcoln1-/- BM-cDCs. 
Closed histograms show staining with the second reagent alone. (B) Dot plots showed 
cell surface expression of CD11c and B220 on WT or Mcoln1-/- BM-pDCs. The gates 
are used for sorting BM-pDCs. The data were representative of three independent 
experiments. 
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3.2 Impaired Toll like receptor 7 and 9 responses in Mcoln1-/- bone marrow derived 
conventional dendritic cells (BM-cDCs). 
  To study roles of Mucolipin-1 in TLR7 and TLR9 responses, GM-CSF induced 
BM-cDCs from WT and Mcoln1-/- were stimulated with a variety of TLR ligands, and 
production of IL-6 and TNF-" was determined by ELISA. No alteration was found in 
responses to a TLR4/MD-2 ligand lipid A and a TLR9 ligand CpG-B (Fig. 4A and B). 
On the other hand, partial, but significant reductions were found in responses to a TLR7 
ligand ssRNA (RNA9.2s-DR) and a TLR9 ligand CpG-A. At lower concentration of 
TLR7 ligands R848 and loxoribine, Mcoln1-/- BM-cDCs showed significantly lower 
responses than WT BM-cDCs. The specificity of TLR7 ligands were verified in Tlr7-/- 
BM-cDCs (Fig. 4A and B). 
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Figure 4. TLR7 and 9 responses are impaired in Mcoln1-/- BM-cDCs. WT, Mcoln1-/- 
or Tlr7-/- BM-cDCs were stimulated with TLR ligands for 24 hr. Production of IL-6 (A) 
or TNF-! (B) was determined by ELISA. The results were represented by the mean 
value with SD from triplicate wells. N.D., Not Detected. *P<0.05; **P<0.01. The data 
were representative of three independent experiments. 
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3.3 Impaired Toll like receptor 7 and 9 responses in Mcoln1-/- bone marrow derived 
plasmacytoid dendritic cells (BM-pDCs). 
  FLT3 induced BM-pDCs were next stimulated with TLR7 and TLR9 ligands. 
Production of IL-6, TNF-" and IFN-" was evaluated by ELISA. Mcoln1-/- BM-pDCs 
showed impaired TLR7 responses to loxoribine and imiquimod (Fig. 5 and 6). TLR7 
ligand Poly U induced TNF-! and IFN-! but not IL-6. Mcoln1-/- BM-pDCs showed 
partial but significant impairment in Poly U-dependent TNF-! and IFN-" production 
(Fig. 5 and 6). In TLR9 responses to CpG-A, only IFN-" production was partially 
impaired (Fig. 6). However, TLR9 responses to CpG-B were not altered at all (Fig. 5A 
and B). The specificity of TLR7 ligands were proved in Tlr7-/- BM-cDCs (Fig. 5 and 6). 
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Figure 5. Impaired TLR7 responses in Mcoln1-/- BM-pDCs. WT, Mcoln1-/- or Tlr7-/- 
BM-pDCs were stimulated with TLR7 and 9 ligands for 24 hr. Production of IL-6 (A), 
TNF-! (B) was determined by ELISA. The results are represented by the average 
values with SD. N.D., Not Detected. *P<0.05; **P<0.01. The data were representative 
of three independent experiments. 
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Figure 6. Impaired TLR7 and TLR9 responses in Mcoln1-/- BM-pDCs. WT, 
Mcoln1-/- or Tlr7-/- BM-pDCs were stimulated with TLR7 and 9 ligands for 24 hr. 
Production of IFN-" was determined by ELISA. The results are represented by the 
average values with SD. N.D., Not Detected. *P<0.05; **P<0.01. The data were 
representative of three independent experiments. 
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3.4 Mucolipin agonist specifically enhances Toll like receptor 7 responses to single 
stranded RNA (ssRNA) in bone marrow derived conventional dendritic cells 
(BM-cDCs). 
  Results shown in Mcoln1-/- BM-cDCs and BM-pDCs (Fig. 4, 5 and 6) suggest that 
mucolipin-1 has a role in TLR7 and TLR9 responses. To confirm that mucolipin-1 is 
required for TLR7 and TLR9 responses, BM-cDCs were stimulated with TLR7 and 
TLR9 ligands in the presence of a synthetic membrane permeable 
dihydroquinolinyloxo-isoindolinedione compound, which is shown to be mucolipin 
agonist, ML1-SA1. ML1-SA1 synergistically induces cytosolic Ca2+ increase with an 
endogenous mucolipin ligand PtdIns(3,5)P2 [45, 59-61]. ML1-SA1 enhanced TLR7 
responses to ssRNA (RNA9.2s-DR and Poly U), but not to small chemical ligands 
(R848 and loxoribine) in BM-cDCs, indicating mucolipin-1 has a role in regulating 
ssRNA recognition by TLR7 (Fig. 7).  
  On the contrary, TLR9 responses to CpG-A were partially attenuated by ML1-SA1, 
indicating that mucolipin-1 may have multiple purposes in regulating CpG-A responses 
(Fig. 7). TLR9 responses to CpG-B were not altered at all by ML1-SA1, indicating 
35 
CpG-B responses are not required mucolipin-1 (Fig. 7). 
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Figure 7. Mucolipin agonist specifically enhances TLR7 responses to ssRNA. 
BM-cDCs were pre-treated with DMSO (Mock) or 10 µM ML1-SA1 for 30 min, and 
then stimulated with TLR7 and 9 ligands at indicated concentrations. After 24 hr 
stimulation, supernatants were harvested, and production of IL-6 (A) or TNF-! (B) was 
determined by ELISA. The results are represented by the average values with SD. 
*P<0.05; **P<0.01. The data were representative of three independent experiments. 
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3.5 Toll like receptor 7 responses to single stranded RNA (ssRNA) is sensitive to 
PIKfyve inhibitor. 
  ML1-SA1 synergistically acts on mucolipin-1 with PtdIns(3,5)P2 [45]. PtdIns(3,5)P2 
is converted by PIKfyve from PtdIns(3)P [62]. PIKfyve complexes with VAC14 and 
FIG4, which are essential in PIKfyve enzyme activity [63, 64]. The FIG4 gene, 
encoding phosphatidylinositol 3,5-bisphosphate 5-phosphatase in human, is important 
in endosomal trafficking [65]. FIG4-/- cells are similar to Mcoln1-/- cells in showing 
enlarged endolysosomes [66]. I reason that PIKfyve may regulate TLR7 and 9 
responses. To address this possibility, BM-cDCs were stimulated with TLR7 and TLR9 
ligands in the presence of PIKfyve inhibitor YM201636. As reported previously [44], 
CpG-B responses were significantly but weakly suppressed by PIKfyve inhibitor (Fig. 
8). Interestingly, CpG-B induced TNF-" production was more resistant to YM201636 
than IL-6 production (Fig. 8B). Much clearer inhibitory effect of PIKfyve inhibitor was 
found in CpG-A induced cytokine production (Fig. 8). Further and complete inhibition 
was observed in TLR7 responses to ssRNA, cytokine production induced by ssRNA 
was dramatically decreased by YM201636 in dose dependent manner (Fig. 8). These 
38 
results suggested that in BM-cDCs, PIKfyve-dependent generation of PtdIns(3,5)P2 was 
more required for TLR7 responses to ssRNA and TLR9 responses to CpG-A than TLR9 
responses to CpG-B.  
  Interestingly, R848 induced IL-6 and TNF-" production was not effected by PIKfyve 
inhibitor (Fig. 8), suggesting that PIKfyve kinase may have different roles in regulating 
TLR7 responses in BM-cDCs.  
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Figure 8. TLR7 responses to ssRNA in BM-cDCs is sensitive to PIKfyve inhibitor. 
BM-cDCs were pre-treated with DMSO (Mock) or PIKfyve inhibitor YM201636 at 
indicated concentrations for 15 min, and then stimulated with TLR7 and 9 ligands. 
After 24 hr, supernatants were harvested, and concentration of IL-6 (A) and TNF-" (B) 
was determined by ELISA. The results are represented by the average values with SD. 
N.D., Not Detected. *P<0.05; **P<0.01. The data were representative of three 
independent experiments. 
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  The inhibitory effect of PIKfyve inhibitor on BM-pDCs was next studied. Consistent 
with the results in BM-cDCs, cytokine production induced by ssRNAs was impaired by 
the PIKfyve inhibitor in BM-pDCs (Fig. 9). Interestingly, TLR7 response to a small 
chemical ligand R848 was impaired significantly in IFN-" production, but not in 
TNF-" production, by PIKfyve inhibitor (Fig. 9), suggesting that PtdIns(3,5)P2 
generation by PIKfyve is specifically required for R848-dependent IFN-" production. 
  Collectively, these data indicate that a PtdIns(3,5)P2-mucolipin-1 axis is required for 
TLR7 responses to ssRNA. 
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Figure 9. TLR7 responses to ssRNA in BM-pDCs is sensitive to PIKfyve inhibitor. 
BM-pDCs were pre-treated with DMSO (Mock) or PIKfyve inhibitor YM201636 at 
indicated concentrations for 15 min, then stimulated with TLR7 ligands. After 24 hr, 
supernatants were harvested, and concentration of TNF-" (A) and IFN-" (B) was 
determined by ELISA. The results are represented by the average values with SD. N.D., 
Not Detected. *P<0.05; **P<0.01. The data were representative of three independent 
experiments. 
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3.6 Toll like receptor 7 responses to lipofectamine-complexed single stranded RNA 
(ssRNA) are not altered by PIKfyve inhibitor in bone marrow derived 
conventional dendritic cells (BM-cDCs) and bone marrow derived plasmacytoid 
dendritic cells (BM-pDCs). 
  Transfection reagents such as lipofectamine promote the uptake of RNA/DNA and 
facilitate RNA/DNA transportation to TLRs compartments, therefore enhance TLRs 
responses [67]. Given that the PtdIns(3,5)P2-mucolipin-1 axis is required for nucleic 
acids transportation, TLR7 and TLR9 might be able to respond to 
lipofectamine-complexed nucleic acids even in the absence of the 
PtdIns(3,5)P2-mucolipin-1 axis. To examine this possibility, BM-cDCs and BM-pDCs 
were stimulated with lipofectamine-complexed nucleic acid ligands in the presence of 
PIKfyve inhibitor. Lipofectamine was able to rescue TLR7 dependent cytokine 
production in BM-cDCs (Fig. 10A) and BM-pDCs (Fig. 10B). In contrast, 
lipofectamine failed to rescue CpG-A responses in BM-cDCs (Fig. 10A) and BM-pDCs 
(Fig. 10B). These results support a possibility that PIKfyve inhibitor impaired ssRNA 
responses by acting on ssRNA transportation. 
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Figure 10. TLR7 responses to lipofectamine-complexed ssRNA are not altered by 
PIKfyve inhibitor in BM-cDCs and BM-pDCs. BM-cDCs (A) and BM-pDCs (B) 
were pre-treated with DMSO (Mock) or PIKfyve inhibitor YM201636 at indicated 
concentrations for 15 min, then stimulated with lipofectamine-complexed nucleic acid 
ligands. After 24 hr, supernatants were harvested, and concentration of IL-6, TNF-" and 
!"
!#$"
!#%"
!#&"
!#'"
!#("
!#)"
!#*"
!#+"
RNA9.2s-DR (µg/ml) 
Lipofectamine 2000
0  25
!"
!#$"
!#%"
!#&"
!#'"
!#("
!#)"
!#*"
Poly U (µg/ml) 
Lipofectamine 2000
0  1
!"
$"
%"
&"
'"
("
)"
RNA9.2s-DR (µg/ml) 
Lipofectamine 2000
0  25
!"
%"
'"
)"
+"
$!"
Poly U (µg/ml) 
Lipofectamine 2000
0  1
TN
F-
!
 (n
g/
m
l)
IF
N
-!
 (n
g/
m
l)
,-./0/123 45%!!!
!"
!#$"
!#%"
!#&"
!#'"
!#("
!#)"
CpG-A (µM) 
Lipofectamine 2000
0  1 
**
!"
("
$!"
$("
%!"
%("
&!"
CpG-A (µM) 
Lipofectamine 2000
0  1 
**
B
BM-pDCs
5/6738"$!"
RNA9.2s-DR (µg/ml) 
Lipofectamine 2000
0  25
!"
!#("
$"
$#("
%"
%#("
&"
&#("
RNA9.2s-DR (µg/ml) 
Lipofectamine 2000
0 
!"
("
$!"
$("
%!"
%("
25
*
IL
-6
 (n
g/
m
l)
TN
F-
!
 (n
g/
m
l)
CpG-A (µM) 
Lipofectamine 2000
0  3 
**
!"
%"
'"
)"
+"
$!"
$%"
!"
$"
%"
&"
'"
("
)"
CpG-A (µM) 
Lipofectamine 2000
0  3 
*****
A
BM-cDCs
Mock YM201636 20nM 100nM 500nM
*P<0.05; **P<0.01
44 
IFN-" was determined by ELISA. The results are represented by the average values 
with SD. *P<0.05; **P<0.01. The data were representative of three independent 
experiments. 
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3.6 Toll like receptor 7 responses to lipofectamine-complexed single stranded RNA 
(ssRNA) are not altered in Mcoln1-/- bone marrow derived conventional dendritic 
cells (BM-cDCs) and bone marrow derived plasmacytoid dendritic cells 
(BM-pDCs). 
  Whether lipofectamine-complexed ssRNA could rescue the TLR7 responses in 
Mcoln1-/- BM-pDCs and BM-cDCs were next studied. Lipofectamine-complexed 
RNA9.2s-DR or Poly U induced cytokine productions in Mcoln1-/- BM-cDCs (Fig. 
11A) and BM-pDCs (Fig. 11B) were comparable to those in WT BM-cDCs and 
BM-pDCs. These results support a possibility that the ligand trafficking rather than 
sensor trafficking is impaired in Mcoln1-/- BM-cDCs.  
  In contrast, lipofectamine-complexed CpG-A induced IFN-" production was partially 
reduced in Mcoln1-/- BM-pDCs (Fig. 11B), which was similar to naked CpG-A 
responses (Fig. 6). Production of IL-6 and TNF-a induced by CpG-A with or without 
lipofectamine was altered in Mcoln1-/- BM-pDCs (Fig. 11B). These data indicate that 
mucolipin-1 may specifically regulate IFN-" production induced by CpG-A. 
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Figure 11. TLR7 responses to lipofectamine-complexed ssRNA are not altered in 
Mcoln1-/- BM-cDCs and BM-pDCs. WT or Mcoln1-/-BM-cDCs (A) and BM-pDCs (B) 
were stimulated with lipofectamine-complexed nucleic acid ligands for 24 hr. 
Production of IL-6, TNF-" in BM-cDCs and production of IL-6, TNF-", IFN-" in 
BM-pDCs was determined by ELISA. The results are represented by the average values 
with SD. **P<0.01. The data were representative of three independent experiments. 
 
 
 
BMpDC
IF
N
-!
 (n
g/
m
l)
IL
6 
(n
g/
m
l)
TN
F-
!
 (n
g/
m
l)
BMcDC
B
RNA9.2s-DR (µg/ml) 
Lipofectamine 2000
0  5 25
!"
#"
$"
%"
&"
'!"
Poly U (µg/ml ) 
Lipofectamine 2000
1 100
!"
("
'!"
'("
#!"
Poly U (µg/ml ) 
Lipofectamine 2000
1 100
!"
!)#"
!)$"
!)%"
!)&"
'"
')#"
Poly U (µg/ml ) 
Lipofectamine 2000
1 100
!"
!)#"
!)$"
!)%"
!)&"
'"
')#"
')$"
WT Mcoln1-/-
*+#!!!,-./0'"1.
+23456"''
RNA9.2s-DR (µg/ml) 
Lipofectamine 2000
0  5 25
!"
("
'!"
'("
#!"
!"
("
'!"
'("
#!"
#("
CpG-A (µM) 
Lipofectamine 2000
0  0.5 1
**
**
!"
!)("
'"
')("
#"
#)("
7"
7)("
CpG-A (µM) 
Lipofectamine 2000
0  0.5 1
!"
!)#"
!)$"
!)%"
!)&"
'"
CpG-A (µM) 
Lipofectamine 2000
0  0.5 1
A
IL
6 
(n
g/
m
l)
TN
F-
!
 (n
g/
m
l)
WT Mcoln1-/-
**P<0.01
47 
3.7 Expression, processing and distribution of Toll like receptor 7 and 9 are not 
altered in Mcoln1-/- bone marrow derived conventional dendritic cells (BM-cDCs). 
  Considering that mucolipin-1 has roles in lysosomal trafficking, trafficking of TLR7 
and 9 may be altered in Mcoln1-/- mice. To address this possibility, expression of these 
TLRs was studied. BM-cDCs were subjected to membrane-permeabilized staining with 
TLR7 or TLR9 mAb [6, 68]. Expressions of TLR7 and TLR9 were not altered in 
Mcoln1-/- BM-cDCs (Fig. 12A). Next, TLR7 and TLR9 were immunoprecipitated. 
Consistent with FACS analyses, no alteration was found in the amount of 
immunoprecipitated TLR7 and TLR9 (Fig. 12B and C). Moreover, proteolytic cleavage 
of TLR7 and TLR9 was not altered (Fig. 12B and C). Given that TLR7 and TLR9 are 
proteolytically cleaved in endolysosomes, trafficking of TLR7 and TLR9 from ER to 
endolysosomes is not likely to be altered in Mcoln1-/- BM-cDCs. To examine the 
distribution of TLR7, I performed a confocal microscopy analysis. Colocalization of 
TLR7 and LAMP2 was not altered in Mcoln1-/- BM-cDCs (Fig. 12D).  
  Collectively, these data indicate that under steady state, the expression, processing 
and distribution of TLR7 is not effected in Mcoln1-/- BM-cDCs. In addition, the 
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expression and processing of TLR9 is not altered in Mcoln1-/- BM-cDCs. 
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Figure 12. TLR7 or TLR9 processing was not altered in mucolipin-1 deficient 
BM-cDCs. (A) Open histograms showed membrane-permeabilized staining with 
anti-TLR7 or TLR9 mAb of WT and Mcoln1-/- BM-cDCs. Gray histograms show 
staining with the second reagent alone. (B, C) WT, Mcoln1-/- and Tlr7-/- BM-cDCs were 
subjected to immunoprecipitation with TLR7 mAb (B) or TLR9 mAb (C). Precipitates 
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were analyzed by immunoprobing with TLR7 or TLR9 polyclonal Ab. Uncleaved and 
C-terminal cleaved form is indicated with the arrows. The data were representative of 
three independent experiments. (D) BM-cDCs were counterstained with anti-TLR7 
mAb (green) and followed by anti-mouse Alexa-488. Cells were counterstained with 
anti-LAMP2 (red) to locate the lysosome. Merged images were also shown. The cells 
were visualized by confocal microscopy. Scale bar, 5 µm. 
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3.8 Internalization of single stranded RNA (ssRNA) is not altered in Mcoln1-/- bone 
marrow derived conventional dendritic cells (BM-cDCs). 
  Results shown in Figure 12 led us to explore regulatory function of mucolipin-1 in 
ssRNA logistics. It is reported that mucolipin-1 has a regulatory function in endocytosis 
[60], I reason that mucolipin-1 may have roles in ssRNA internalization. WT and 
Mcoln1-/- BM-cDCs were incubated with FITC-labeled RNA9.2s-DR in a time 
dependent manner at 37". Fluorescence on the cell surface was quenched by trypan 
blue. Internalized ssRNA was analyzed by flow cytometry. No alteration was found 
between WT and Mcoln1-/- BM-cDCs (Fig. 13B). These results suggest that mucolipin-1 
is dispensable for ssRNA internalization. 
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Figure 13. Endocytosis of ssRNA is not altered in Mcoln1-/- BM-cDCs. WT and 
Mcoln1-/- BM-cDCs were stimulated with 5 !g/ml RNA9.2s-DR-FITC in indicating 
time at 37". Fluorescence was measured by FACSCalibur without quenching (A) or 
quenching with 2 mg/ml of trypan blue (B).  
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3.9 Single stranded RNA (ssRNA) transportation to lysosomes is impaired in 
Mcoln1-/- bone marrow derived conventional dendritic cells (BM-cDCs). 
  Mucolipin-1 is a gene responsible for mucolipidosis type IV [69], in which 
metabolites accumulate in lysosomes due to altered lysosomal trafficking. I reason that 
nucleic acids might belong to metabolites that require mucolipin-1 for proper trafficking 
to lysosomes. To address this possibility, Mcoln1-/- BM-cDCs were stimulated with 
rhodamine-labeled ligands such as CpG-A, CpG-B, RNA9.2s-DR or Poly U. 
Colocalization of these ligands with a lysosome marker lysotracker was studied by 
confocal microscopy. CpG-B showed very weak colocalization with lysotracker. 
Mcoln1-/- BM-cDCs did not show any alteration in CpG-B distribution (Fig. 14A). 
Similarly CpG-A colocalization with lysotracker was not altered in Mcoln1-/- BM-cDCs 
(Fig. 14B). In contrast to CpG-B and CpG-A, TLR7 ligands, RNA9.2s-DR and Poly U, 
showed high colocalization with lysotracker in WT BM-cDCs and the colocalization 
was significantly impaired in Mcoln1-/- BM-cDCs (Fig. 14C and D). These results 
indicate that an important role of mucolipin-1 in ssRNA trafficking into lysosomes but 
not in DNA trafficking into lysosomes. In addition, intracellular transportation of 
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ssRNA and DNA are likely to be regulated by different mechanisms.  
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Figure 14. ssRNA transportation to lysosome is impaired in Mcoln1-/- BM-cDCs. 
WT and Mcoln1-/- BM-cDCs were stimulated with 1 !M CpG-B-rhodamine (A), 1 !M 
CpG-A-rhodamine (B), 10 µg/ml RNA9.2s-DR-rhodamine (C) or 10 µg/ml Poly 
U-rhodamine (D) for 90 min. To visualize lysosomes, cells were incubated with 
Lysotracker-Green for 30 min before analyses by confocal microscopy. Statistical 
analyses using correlation coefficient are also shown. **P<0.01; ***P<0.001. Scale bar, 
5 µm. 
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3.10 Single stranded RNA transportation to lysosomes is enhanced by mucolipin 
agonist ML1-SA1 in bone marrow derived conventional dendritic cells (BM-cDCs). 
  Mucolipin agonist ML1-SA1 enhances lysosomal exocytosis [60]. Considering that 
TLR9 responses to CpG-A were impaired by mucolipin agonist ML1-SA1 in BM-cDCs 
(Fig. 7), the transportation of CpG-A to lysosome may be altered. To address this 
possibility, ML1-SA1 pre-treated BM-cDCs were stimulated with rhodamine-labeled 
CpG-B and CpG-A. ML1-SA1 did not alter the colocalization of CpG-B with 
lysotracker (Fig. 15A). However, ML1-SA1 significantly impaired the colocalization of 
CpG-A with lysotracker in BM-cDCs were (Fig. 15B). These results suggest that 
mucolipin-1 negatively regulates CpG-A transportation to lysosome. 
  ssRNA transportation to lysosomes was reduced in Mcoln1-/- BM-cDCs (Fig. 14C 
and D), and ML1-SA1 specifically enhanced ssRNA responses (Fig. 7), I next examine 
the transportation of ssRNA in the presence of ML1-SA1. Colocalization of 
RNA9.2s-DR and Poly U with lysotracker was significantly upregulated by ML1-SA1 
(Fig. 15C and D). These results indicate that an important role of mucolipin-1 in ssRNA 
trafficking into lysosomes. Moreover, the data suggest that DNA and ssRNA employ 
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different transportation pathways.  
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Figure 15. ssRNA transportation to lysosomes is enhanced by mucolipin agonist 
ML1-SA1 in BM-cDCs. BM-cDCs were pre-treated with DMSO (Mock) or 10 µM 
ML1-SA1 for 30 min. BM-cDCs were stimulated with 1 µM CpG-B-rhodamine (A), 1 
µM CpG-A-rhodamine (B), 10 µg/ml RNA9.2s-DR-rhodamine (C) or 10 µg/ml Poly 
U-rhodamine (D) for 90 min. To visualize lysosomes, cells were incubated with 
Lysotracker-Green for 30 min before analyses by confocal microscopy. Statistical 
analyses using correlation coefficient are also shown. *P<0.05; **P<0.01; ***P<0.001. 
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3.11 Single stranded RNA transportation to lysosomes is impaired by PIKfyve 
inhibitor in bone marrow derived conventional dendritic cells (BM-cDCs). 
  PIKfyve converts PtdIns(5)P into PtdIns(3,5)P2, which is an endogenous ligands for 
mucolipin-1 [44, 63, 64]. Given that mucolipin-1 regulates ssRNA transportation, 
PIKfyve inhibitor YM201636 may inhibit ssRNA transportation to lyososomes. To 
address this possibility, YM201636 pre-treated BM-cDCs were stimulated with 
rhodamine-labeled CpG-A and RNA9.2s-DR. Confocal microscopy images showed that 
the colocalization of CpG-A and RNA9.2s-DR with lysotracker is drastically impaired 
by PIKfyve inhibitor (Fig. 16A and B), indicating PIKfyve has a role in ssRNA and 
DNA transportation to lysosomes. I next examine whether the contrary cytokine 
production results in lipofectamine-complexed CpG-A and ssRNA in the presence of 
PIKfyve inhibitor is due to the transportation of nucleic acids regulated by 
lipofectamine. Lipofectamine failed to rescue CpG-A trafficking to lysosomes in the 
presence of PIKfyve inhibitor (Fig. 16A). As expected, the suppressive effect of 
PIKfyve inhibitor in ssRNA transportation to lysosome was abolished by lipofectamine 
(Fig. 16B). 
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  Collectively, these results indicate that the PtdIns(3,5)P2-mucolipin-1 axis pathway is 
required for ssRNA transportation to lysosomes. 
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Figure. 16 ssRNA transportation to lysosomes is impaired by PIKfyve inhibitor in 
BM-cDCs. BM-cDCs were pre-treated with DMSO (Mock) or 500 nM YM201636 for 
15 min. BM-cDCs were stimulated with 1 µM naked CpG-A-rhodamine and 
lipofectamine-complexed CpG-A-rhodamine (A), 10 µg/ml naked 
RNA9.2s-DR-rhodamine and lipofectamine-complexed RNA9.2s-DR-rhodamine (B) 
for 90 min. To visualize lysosomes, cells were incubated with Lysotracker-Green for 30 
min before analyses by confocal microscopy. LF2000: lipofectamine 2000. Statistical 
analyses using correlation coefficient are also shown. ***P<0.001. 
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3.12 Toll like receptor 7 responses are altered in Mcoln1-/- bone marrow chimeric 
mice. 
  To further address the immunological relevance of mucolipin-1 in innate immune 
responses, BM chimeric mice were used in in vivo tests. B cells were purified from 
spleen of WT, Mcoln1-/- and BM chimeric mice reconstituted with WT or Mcoln1-/- BM 
cells. mRNA was isolated from splenic B cells and subjected to reverse transcript PCR. 
PCR primers were designed according to mucolipin-1 knock out strategy [58]. 480 bp 
PCR fragment designed for WT allele was undetectable in the splenocyte from BM 
chimeric mice reconstituted with Mcoln1-/- BM cells, confirming that all the B cells 
were from Mcoln1-/- BM cells (Fig. 17A). Because cell surface expression of CD23 was 
significantly decreased in Mcoln1-/- B cells (Fig. 17B), peripheral blood mononuclear 
cells (PBMCs) were obtained from facial vein of BM chimeric mice and were stained 
with markers B220, CD21 and CD23. Because of this phenotype, the chimerism of 
Mcoln1-/- BM chimeric mice can be further confirmed by cell surface CD23 expression. 
All the B cells showed low CD23 expression, confirming that all the B cells were 
replaced with Mcoln1-/- B cells (Fig. 17C). WT and Mcoln1-/- BM chimeric mice (10 
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mice for each group) were administrated with R848 (2 µg/mouse) by vena ophthalmica 
injection. Sera from each mouse were obtained 4 days before ligands injection and were 
used as background control in ELISA. Two hours after injection of R848, sera were 
collected from facial vein. Production of IL-6 and IL-12p40 was detected by ELISA. 
Both IL-6 and IL-12p40 productions were partially but significantly altered in Mcoln1-/- 
BM chimeric mice (Fig. 17D and E). These data further proved the importance of 
mucolipin-1 in TLR7 responses in vivo.  
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Figure 17. TLR7 responses are altered in Mcoln1-/- BM chimeric mice. mRNA was 
purified from splenic B cells of WT mice, Mcoln1-/- mice, WT BM recipient mice and 
Mcoln1-/- BM recipient mice separately. In reverse transcription PCR, primers targeting 
Mcoln1-/- were designed based on previous report [58], Actin! detection was regarded as 
control (A). B cells, that were purified from WT, Mcoln1-/- (B) Chimeric mice (C), 
stained with markers B220, CD21 and CD23. Cell surface expression of staining 
markers were detected by FACSCalibur. Serum samples were obtained 4 days before 
injection as background control (Pre-serum). WT BM chimeric mice (n=10) and 
Mcoln1-/- BM chimeric mice (n=10) were intravenously injected with R848 2 µg/mouse 
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for 2 hr. Serum samples were obtained, concentration of IL-6 (D) and IL-12p40 (E) 
were detected by ELISA. Data represent the Mean. *P<0.05. 
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4. Discussion 
  The present study shows that a PtdIns(3,5)P2-muclipin-1 axis has a role in ssRNA 
transportation to lysosome in bone marrow dendritic cells. Mcoln1-/- BM-cDCs and 
BM-pDCs were significantly impaired in the TLR7 responses to ssRNA. The synthetic 
mucolipin agonist (ML1-SA1) synergistically activates mucolipin with endogenous 
ligand PtdIns(3,5)P2 [60, 61]. BM-cDCs pre-treated with ML1-SA1 showed enhanced 
responses to ssRNA, demonstrating the importance of mucolipin-1 in TLR7 responses, 
particularly in ssRNA recognition. BM-cDCs pre-treated with PIKfyve inhibitor 
demonstrated the important role of a PtdIns(3,5)P2-muclipin-1 axis in ssRNA 
recognition (Table 4). 
  PtdIns(3,5)P2 is low-abundance endolysosome-specific phosphoinositide. FIG4 
deficient cells, which result in 50 % decrease in PtdIns(3,5)P2 levels, are similar to 
mucolipin-1 deficient cells in that both cells show enlarged endolysosomes and 
impaired endocytic trafficking [66]. Recent studies show that PtdIns(3,5)P2 is able to 
induce calcium influx/efflux by activating transient receptor potential mucolipin-1, 
mucolipin-2 and mucolipin-3 [45, 70]. Other phosphoinositides are not able to activate 
70 
mucolipin family [45, 70]. PtdIns(3,5)P2 is produced from PtdIns(3)P by PtdIns(5)K 
PIKfyve complex that is localized in late endosomes and lysosomes [71]. The present 
studies showed that TLR7 responses to RNA9.2s-DR and Poly U were diminished by 
PIKfyve inhibitor YM201636. These data demonstrated that PIKfyve dependent 
PtdIns(3,5)P2 generation is important for TLR7 responses to ssRNA. Although 
BM-cDCs and BM-pDCs lacking mucolipin-1 showed significantly impaired cytokine 
production in responses to RNA9.2s-DR or Poly U, the cytokine production was still 
detectable. These results indicate a possibility that PtdIns(3,5)P2 activates another 
molecule in addition to mucolipin-1. It is possible that mucolipin-2 and mucolipin-3 
have a redundant role in TLR7 responses. Dong et al. report that mucolipin-1 is more 
sensitive than mucolipin-2 and mucolipin-3 to PtdIns(3,5)P2 [45]. Mucolipin-1, among 
the target proteins of PtdIns(3,5)P2, is likely to be predominant mediator in TLR7 
responses.  
  Phosphoinositides are generated in a compartment-specific manner and have 
important roles in endosomal trafficking [72]. We hypothesized that Mocolipin-1 
activation via PtdIns(3,5)P2 regulates TLR7 logistics. However, TLR7 processing, 
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which reflected TLR7 trafficking from ER to endosomes [14, 19], was not altered in 
Mcoln1-/- BM-cDCs. Confocal microcopy images showed the colocalization of TLR7 
and LAMP2 was not altered in Mcoln1-/- BM-cDCs. These data suggest that under 
steady state, mucolipin-1 does not influence TLR7 trafficking. 
  Kuo et al. show that class III PI3K is essential for CpG-B uptake. Class III PI3K 
inhibitor (wortmannin) and a loss-of-function mutation in class III PI3K impairs the 
CpG-B uptake [73]. Class III PI3K converts PtdIns into PtdIns(3)P, which is the 
substrate of PIKfyve [74]. It has been shown that PIKfyve is required for CpG-B 
transportation to LAMP1+ compartments [44]. Mucolipin-1 has a role in lysosome 
trafficking, and this process can be inhibited by PIKfyve inhibitor or the lack of FIG4 
[60]. PIKfyve is known to form a complex with VAC14 and FIG4, and the complex 
activity is depended on FIG4 [65, 75]. Considering TLR7 processing was not altered in 
Mcoln1-/- BM-cDCs, I hypothesized that TLR7 responses were impaired due to altered 
ligand trafficking. Consistent with hypothesis, ssRNAs transportation to lysosome was 
significantly impaired in Mcoln1-/- BM-cDCs. Moreover, mucolipin-1 agonist ML1-SA1 
significantly enhanced ssRNA transportation to lysosomes in BM-cDCs. These results 
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indicated that ssRNA transportation is dependent on the activation of mucolipin-1. 
Current data showed that the PtdIns(3,5)P2-mucolipin-1 axis is required for ssRNA 
responses, I next examined whether PIKfyve regulated ssRNA transportation. As 
expected, PIKfyve inhibitor drastically impaired ssRNA transportation to lysosomes. 
Collectively, these results suggest the PtdIns(3,5)P2-mucolipin-1 axis regulates ssRNA 
transportation to lysosomes. It is notable that impaired ssRNA transportation in the 
presence of PIKfyve inhibitor was more remarkable than that in Mcoln1-/- BM-cDCs. 
These data indicate that, in addition to mucolipin-1, as yet unknown effectors 
downstream of PtdIns(3,5)P2 contribute to ssRNA transportation. 
  Transfection reagents such as lipofectamine are able to facilitate the uptake and 
delivery of NAs, and protect NAs from degradation by nucleases. Therefore, NAs 
complexed with transfection reagents enhance the TLRs responses. Interestingly, the 
effect of PIKfyve inhibitor was abolished by complex formation with lipofectamine. 
Additionally, lipofectamine-complexed ssRNA were able to rescue TLR7 responses in 
Mcoln1-/- BM-cDCs and BM-pDCs. It is reported that synthetic 
lipofectamine-complexed RNA/DNA potentially mimic viral particles, thus promoting 
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uptake of RNA [76]. The transportation of RNA via viral particle may be distinct from 
that of naked RNA. Confocal microscopy images revealed that lipofectamine is able to 
rescue ssRNA transportation to lysosomes in the presence of PIKfyve inhibitor. These 
data indicate that lipofectamine might facilitate RNA localization in lysosomes by 
enabling PIKfyve kinase independent RNA trafficking. 
  PIKfyve inhibitor significantly impaired CpG-A responses. Of note, PIKfyve 
inhibitor also impaired lipofectamine-complexed CpG-A responses. Confocal 
microscopy images showed that PIKfyve inhibitor drastically impaired naked CpG-A 
and lipofectamine-complexed CpG-A transportation to lysosomes. Nevertheless, 
CpG-A transportation to lysosomes was not altered in Mcoln1-/- BM-cDCs, suggesting 
that as yet unknown effectors other than mucolipin-1 are responsible for CpG-A 
transportation. Lipofectamine-mediated CpG-A transportation seems to be PtdIns(3,5)P2 
dependent. Given that lipofectamine-mediated RNA transportation is independent of 
PtdIns(3,5)P2, DNA transportation is distinct from RNA transportation even in the 
presence of lipofectamine. 
  The mucolipin agonist ML1-SA1 did not enhance, but significantly impaired CpG-A 
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responses in BM-cDCs. Consistent with this, ML1-SA1 significantly suppressed 
CpG-A trafficking into lysosomes. However, Mcoln1-/- BM-cDCs showed impaired 
CpG-A responses. It is reported that ML1-SA1 may also activate mucolipin-2 and 
mucolipin-3 [57, 59], suggesting that mucolipin-2 or mucolipin-3 may negatively 
regulate CpG-A transportation to lysosomes. If mucolipin-1 does not regulate CpG-A 
transportation, what is the role of mucolipin-1 in CpG-A responses? TLR9 translocation 
is important for TLR9 recognition of ligands [18], moreover, Sasai et al. show that 
TLR9 translocation to lysosome related organelles (LROs) is regulated by 
adapter-related protein complex-3 (AP3) [77]. Vergarajauregui and Puertollano show 
that AP3 regulates mucolipin-1 trafficking to lysosome by association with di-leucine 
motifs of mucolipin-1 [78]. Although TLR9 processing demonstrated that under steady 
state TLR9 trafficking from ER to endolysosomes might not alter, the distribution of 
TLR9 after stimulation in the endolysosomal systems might be slightly altered in 
Mcoln1-/- cDCs. Further study is required to address this issue.  
  PIKfyve inhibitor only slightly impaired CpG-B induced responses. These results 
indicate that mucolipin-1 has a minimal role in CpG-B responses. In contrast to CpG-A 
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responses, ML1-SA1 did not alter CpG-B responses. Confocal microscopy images 
revealed ML1-SA1 did not alter the CpG-B transportation to lysosomes, indicating 
CpG-B transportation is likely to be distinct from CpG-A transportation.  
  In Mcoln1-/- BM-cDCs, CpG-B induced IL-6 and TNF-" production was not altered, 
whereas CpG-A responses were impaired. Confocal microscopy images showed that 
neither CpG-B nor CpG-A transportation to lysosomes were altered in Mcoln1-/- 
BM-cDCs, indicating that mucolipin-1 may not regulate their transportation. It is 
arbitrary to exclude a possibility that TLR9 trafficking in endolysosomal system is 
slightly altered in Mcoln1-/- BM-cDCs.  
  TLR7 responses to small chemical ligands were impaired in Mcoln1-/- BM-cDCs and 
BM-pDCs (Table 4). However, neither mucolipin agonist nor PIKfyve inhibitor altered 
TLR7 responses to these small chemical ligands in BM-cDCs. TLR7 responses to small 
chemical ligands may not require PtdIns(3,5)P2-dependent mucolipin-1 activation, 
suggesting that mucolipin-1 has another role in TLR7 responses in addition to 
RNA-trafficking. Interestingly, Christoph. et al. report that in CD14-/- BM-cDCs, TLR7 
responses to lower concentration of imiquimod is profoundly impaired. Nevertheless, 
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chemical ligands at higher concentration are able to activate CD14-/- BM-cDCs. 
Moreover, CD14 is essential in ligands uptake and transportation to endolysosome [21]. 
Chemical ligands at higher doses may be able to activate a mucolipin-1-independent 
trafficking pathway, and thereby to activate TLR7 in Mcoln1-/- DCs. It is important to 
study all the trafficking pathways employed by TLR7 ligands and TLR9 ligands. It is 
possible that CD14 and mucolipin-1 contribute to the same trafficking pathway. To note 
that chemical ligands (R848, loxoribine and imiquimod) induced IFN-" production was 
partially decreased in Mcoln1-/- BM-pDCs. It is reported that TLR7 mediated IFN-" 
production requires mammalian target of rapamycin (mTOR), rapamycin significantly 
inhibits loxoribine (TLR7 chemical ligand) induced IFN-" production in BM-pDCs 
[79]. Wong et al. report that a loss-of-function mutant of mucolipin-1 impaired activity 
of target of rapamycin complex 1 (TORC1) in Drosophila [80]. It is possible that 
decreased IFN-" production induced by chemical ligands is due to impaired mTOR 
activation in Mcoln1-/- BM-pDCs.  
  Additionally, in vivo experiments further showed that mucolipin-1 has regulatory 
functions in TLR7 responses to chemical ligands. Considering that TLR7 is important 
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in antiviral responses, Mcoln1-/- mice may be sensitive to viral infection. In addition, 
current data showed that mucolipin-1 has a role in TLR7 responses to Poly U, a uridine 
(U)-ssRNA which derives from human immunodeficiency virus-1 (HIV-1) [81]. Further 
study on viral infection using Mcoln1-/- mice may shed a light on the importance of 
mucolipin-1 in antiviral defenses.  
  Human mutations of mucolipin-1 cause Mucolipidosis type IV, a lysosomal storage 
disease characterized by abnormally large lysosomes containing electron-dense 
inclusions and lipid storage bodies [69, 82]. Cells from Mucolipidosis type IV patients 
present an abnormal endocytosis process of the membrane components to late 
endosomes and lysosomes, finally leading to abnormal lysosomal storage [83]. 
Lysosome exocytosis is also affected by Mucolipidosis type IV [84]. RNA is likely to 
be aberrantly transported and accumulated in lysosomes in Mucolipidosis type IV. It is 
interesting to study TLR7 and 9 responses in Mucolipidosis type IV. Most LSDs are 
due to the defective lysosomal enzymes activities, which result in abnormal lysosomal 
accumulation. In Niemann-Pick (NP) disease sphingomyelins (SMs) accumulate in 
lysosomes, hence inhibit mucolipin-1 mediated lysosomal trafficking [59]. Lipid 
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metabolism may influence innate immunity by modulating mucolipin-1 dependent 
transportation of RNA or DNA. 
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Table. 4 Summary in functional results 
Ligands TLR Cytokine BM-cDCs BM-pDCs 
Mcoln1-/- YM201636 ML1-SA1 Mcoln1-/- YM201636 
CpG-A 
TLR9 
IL-6      
TNF-"      
IFN-"     
CpG-A 
LF2000* 
IL-6     
TNF-"     
IFN-"     
CpG-B IL-6         
TNF-"      
RNA9.2s- 
DR 
TLR7 
IL-6       N.D. N.D. 
TNF-"       N.D. N.D. 
IFN-"    N.D. N.D. 
RNA9.2s- 
DR LF2000 
IL-6        
TNF-"         
IFN-"     
Poly U 
IL-6 N.D. N.D   N.D. N.D. 
TNF-" N.D. N.D     
IFN-"     
Poly U 
LF2000 
IL-6       
TNF-"     
IFN-"     
R848 
TLR7 
IL-6      
TNF-"      
IFN-"     
Loxoribne 
IL-6      
TNF-"      
IFN-"     
Imiquimod 
IL-6     
TNF-"     
IFN-"     
*: lipofectamine 2000. !: decrease. : not altered. ": increase. N.D.: not detected. 
 Solid Grey: not tested. 
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